Lipertance (Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate)

Amlodipine relaxes vascular smooth muscle by blocking calcium channels, perindopril reduces angiotensin II formation through ACE inhibition, and atorvastatin decreases cholesterol synthesis by inhibiting HMG‑CoA reductase. Together they provide complementary blood‑pressure reduction and lipid‑lowering effects.

The specific dose of Lipertance is determined by the prescribing clinician based on the patient’s blood‑pressure readings, lipid profile, renal and hepatic function, and overall cardiovascular risk. Dosage adjustments are made individually.

Amlodipine, perindopril and atorvastatin each have specific pregnancy and lactation considerations. Generally, these agents are not recommended unless the potential benefit justifies the risk. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lipertance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lipertance offers a fixed‑dose combination, simplifying the regimen by reducing pill burden and potentially improving adherence. Pharmacologically, the three active ingredients provide the same mechanisms as when taken individually, but the combination may offer convenience and consistent dosing.

Store Lipertance at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, excessive heat and direct sunlight to maintain stability.

Lipertance is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include angioedema, severe hypotension, hepatotoxicity, rhabdomyolysis, pancreatitis and anaphylactic reactions. Patients should seek immediate medical attention if they experience swelling of the face or throat, unexplained muscle pain, dark urine, severe abdominal pain, or signs of an allergic reaction.

Lipertance is contraindicated in patients with known hypersensitivity to any of its components, severe hepatic impairment, active liver disease, or a history of angioedema related to ACE‑inhibitor therapy. It should also be avoided in individuals with uncontrolled hypotension.